SCHEMBL97548

SCHEMBL97548

O=C1/C(=N\O)CCn2c(=O)[nH]c3cccc1c32

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.43
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
ADRB2 P07550 2/20 0.38
HTR1A P08908 9/20 0.37
DRD2 P14416 4/20 0.37
DRD3 P35462 4/20 0.37
OPRM1 P35372 2/20 0.37
DAO P14920 2/20 0.36
AURKA O14965 1/20 0.33
KDM4E B2RXH2 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL134748 1.00 HTR3A (0.43) HTR3AALDH1A1CYP1A2CYP2C19ADRB2
SCHEMBL134747 1.00 HTR3A (0.43) HTR3AALDH1A1CYP1A2CYP2C19ADRB2
SCHEMBL10830907 0.81 HTR3A (0.47) HTR3AADRB2HTR1ADRD2DRD3
SCHEMBL13703832 0.76 HTR3A (0.39) HTR3AALDH1A1ADRB2HTR1ADRD2
SCHEMBL7003840 0.76 KDM4E (0.38) HTR3AALDH1A1CYP1A2CYP2C19KDM4E
SCHEMBL7003839 0.76 KDM4E (0.38) HTR3AALDH1A1CYP1A2CYP2C19KDM4E
SCHEMBL97632 0.74 HTR3A (0.48) HTR3AADRB2HTR1ADRD2DRD3
SCHEMBL98086 0.72 KDM4E (0.40) HTR3AALDH1A1CYP1A2CYP2C19HTR1A
SCHEMBL15840472 0.70 HTR3A (0.51) HTR3AADRB2HTR1ADRD2DRD3
SCHEMBL7160420 0.70 PARP1 (0.52) HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3190114-B1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT INTERVET INT BV (NL) 2019-11-06 EP disclosed
EP-2935275-B9 AN IMPROVED PROCESS FOR MAKING ZILPATEROL INTERVET INT BV (NL) 2017-10-11 EP disclosed
EP-3190114-A1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT Intervet International B.V. (NL) 2017-07-12 EP disclosed
US-9630967-B2 Process for making zilpaterol INTERVET INC. (US) 2017-04-25 US disclosed
US-9630967-B2 Process for making zilpaterol INTERVET INC. (US) 2017-04-25 US disclosed
EP-2935275-B1 AN IMPROVED PROCESS FOR MAKING ZILPATEROL INTERVET INT BV (NL) 2017-03-08 EP disclosed
EP-2535340-B1 Process for making zilpaterol and salts thereof INTERVET INT BV (NL) 2016-04-27 EP disclosed
US-20150315195-A1 AN IMPROVED PROCESS FOR MAKING ZILPATEROL INTERVET INC. (US) 2015-11-05 US disclosed
US-20150315195-A1 AN IMPROVED PROCESS FOR MAKING ZILPATEROL INTERVET INC. (US) 2015-11-05 US disclosed
EP-2142553-B1 PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF INTERVET INT BV (NL) 2015-08-19 EP disclosed
US-8362006-B2 Processes for making zilpaterol and salts thereof INTERVET INTERNATIONAL B.V. (NL) 2013-01-29 US disclosed
US-8343956-B2 Process for making a crystalline zilpaterol salt INTERVET INTERNATIONAL B.V. (NL) 2013-01-01 US disclosed
US-8343956-B2 Process for making a crystalline zilpaterol salt INTERVET INTERNATIONAL B.V. (NL) 2013-01-01 US disclosed
EP-2535340-A2 Process for making zilpaterol and salts thereof Intervet International B.V. (NL) 2012-12-19 EP disclosed
US-20120058189-A1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT INTERVET INTERNATIONAL B.V. (NL) 2012-03-08 US disclosed
US-20120058189-A1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT INTERVET INTERNATIONAL B.V. (NL) 2012-03-08 US disclosed
WO-2010070004-A1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT INTERVET INTERNATIONAL B.V. (NL) 2010-06-24 WO disclosed
US-20100121050-A1 PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF INTERVET INTERNATIONAL B.V. (NL) 2010-05-13 US disclosed
US-20100121050-A1 PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF INTERVET INTERNATIONAL B.V. (NL) 2010-05-13 US disclosed
WO-2008119754-A1 PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF INTERVET INTERNATIONAL B.V. (NL) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121050-A1 PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF SLC39A11, SLC39A3, ZFR HTR3A 4366/4885ALDH1A1 2559/4885CYP1A2 656/4885
US-20120058189-A1 PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT ZFX, SLC39A11, ZNF277 HTR3A 4341/4885ALDH1A1 4450/4885CYP1A2 1679/4885
US-20150315195-A1 AN IMPROVED PROCESS FOR MAKING ZILPATEROL PPIP5K2, PPIA, ITPA HTR3A 4024/4885ALDH1A1 1754/4885CYP1A2 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.